Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Update

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,250,000 shares, an increase of 26.5% from the February 28th total of 2,570,000 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average trading volume of 926,100 shares, the days-to-cover ratio is currently 3.5 days.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. OFI Invest Asset Management acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $28,000. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 15 shares during the period. Finally, Avalon Trust Co bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target on the stock. UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Citigroup lowered their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $966.88.

Regeneron Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ REGN traded down $8.08 during midday trading on Tuesday, reaching $626.15. 330,414 shares of the company’s stock were exchanged, compared to its average volume of 673,716. The business’s fifty day moving average price is $682.93 and its two-hundred day moving average price is $791.84. Regeneron Pharmaceuticals has a 52-week low of $618.51 and a 52-week high of $1,211.20. The stock has a market capitalization of $68.45 billion, a PE ratio of 16.38, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business posted $11.86 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.